Cerebral infarction accounts for more than 85% of cerebrovascular diseases. Most of the cerebral infarction is caused by the rupture of atherosclerotic plaque or embolism of cardiac origin causing cerebral vascular blockage, or by the local aggregation of platelets in the blood due to the damage of arterial endothelium, which triggers the “coagulation waterfall” and the formation of blood clots, the result of which is the acute occlusion of blood vessels, causing The result is acute vascular occlusion, causing ischemia and tissue necrosis. Antiplatelet therapy can inhibit the occurrence and development of thrombosis by inhibiting platelet aggregation, and therefore plays an important role in the prevention of ischemic cerebrovascular disease. John, a British pharmacologist, was awarded the Nobel Prize in Medicine for his discovery of drugs to resist platelet agglutination and prevent thrombosis. In the prevention and treatment of cardiovascular diseases, anti-platelet drugs play an important role, and their efficacy in inhibiting platelet aggregation can last the lifetime of platelets, thus more effectively avoiding the occurrence of cardiovascular and cerebrovascular diseases. Experiments have shown that adhering to one anti-platelet drug per day can better inhibit the newly generated platelets. In general, this effect is lost 48 hours after stopping aspirin. This is the reason why the standard method of taking anti-platelet drugs is once a day. And since human platelets are constantly renewing, they have a lifespan of about 10 days, so it is important to take anti-platelet drugs for a long time. Recent studies have also found that some patients have poor results after taking anti-platelet drugs and do not have the desired effect of inhibiting platelet coagulation, and some have repeated cardiovascular events. There are many reasons for this, including the so-called “anti-platelet drug resistance”; we can also not exclude that the drug dose is insufficient or irregularly taken. Some patients reduce the dose or intermittently take antiplatelet drugs because they are overly worried about the side effects of antiplatelet drugs, which will affect the clinical effect of antiplatelet drugs. Therefore, in the prevention of ischemic cerebrovascular disease, if there are no contraindications, antiplatelet drugs need to be taken for life. The preventive effect of long-term antiplatelet drugs on ischemic cerebrovascular disease is confirmed by medical guidelines in the United States, Europe and China.